Activist Investing LLC has announced the acquisition of Titan Pharmaceuticals, Inc’s. (NASDAQ: TTNP) common stock. According to Activist Investing’s CEO, David E. Lazar. The firm invested in Titan Pharmaceuticals after the latter expressed interest in strategic alternatives such as reverse mergers. The firm will monitor its development as it believes that Titan Pharmaceuticals could be of great value.
Activist Investing specialises in reverse mergers and other opportunities caused by particular events. The investment firm’s CEO also has International and domestic expertise in acquisitions, mergers, debt financing, capital restructuring, due diligence, audit preparation, accounting, and operations.
Titan Pharmaceuticals uses its ProNeura platform to develop therapies
Titan Pharmaceuticals is a biotechnology company that develops therapies using its ProNeura technology. The company believes that its technology platform could potentially treat several chronic conditions that require patients to have therapeutic levels of the drug in their systems throughout the day.
The platform develops a solid matrix that a physician places in the inner part of the upper arm for the duration of treatment. Using this technique, the company has created several drugs, including Probuphine. It was to treat patients in a manner that would reduce opioid relapse. It also treats moderate and severe pruritus.
Benefits of subdermal drug delivery
Since ProNeura creates a subdermal delivery drug system, it can offer patients additional benefits. The drug could be implanted long-term to ensure a patient receives non-fluctuating levels of medication. It could also be given short-term for about six months to ensure the patients remain compliant with their therapy. Furthermore, the drug is safe, tolerable, and effective.
The implant received approval in the E.U, Canada and the U.S. However, in October 2020, the company announced the discontinuation of the drug in the U.S. this move would allow Titan to focus on developing more therapies using its proprietary technology.
Titan Pharmaceuticals has many patents for products it developed using the ProNeura Technology. It can apply these platforms in various regions such as South Africa, Australia, Mexico, Canada, India, Hong Kong, Singapore, South Korea, Japan, Europe, and the U.S. The expiration date for these patents is 2032. Titan still plans to file for other patents.
